A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
Stopped Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly tolerated.
Conditions
Interventions
- DRUG: bevacizumab
- DRUG: sunitinib
- DRUG: placebo
Sponsor
Genentech, Inc.